Chris Garabe­di­an's Xon­toge­ny shep­herds its first biotech through a $10M start­up round

Four months af­ter Chris Garabe­di­an lined up $15 mil­lion to back his new play to shep­herd a flock of biotech star­tups, the Xon­toge­ny CEO has un­veiled his first new project.

Wel­come Lan­dos, a biotech up­start that is com­ing from the lab of Vir­ginia Tech’s Josep Bas­saganya-Ri­era. The re­searcher, who’s cred­it­ed with sev­er­al biotech star­tups, has lined up a new drug — BT-11, an oral treat­ment of Crohn’s dis­ease and ul­cer­a­tive col­i­tis — which is on the thresh­old of its first clin­i­cal study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER